149 related articles for article (PubMed ID: 11584679)
21. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
22. Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells.
Thomas HC; Lamé MW; Dunston SK; Segall HJ; Wilson DW
Toxicol Appl Pharmacol; 1998 Aug; 151(2):236-44. PubMed ID: 9707500
[TBL] [Abstract][Full Text] [Related]
23. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
24. Systemic evaluation of platelet and leukocyte activation and interaction in a rat model of pulmonary arterial hypertension.
Hu XS; Du CQ; Zeng CL; Yao L; Zhang FR; Wang K; Chen JZ; Li N; Hu H
Cardiology; 2010; 117(1):44-53. PubMed ID: 20924177
[TBL] [Abstract][Full Text] [Related]
25. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
[TBL] [Abstract][Full Text] [Related]
26. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
27. [Preventive effects of tetrandrine on pulmonary hypertension and right ventricular hypertrophy in rats induced by monocrotaline].
Jin X; Zhang X; Xing J; Liu K; Wang H
Zhongguo Zhong Yao Za Zhi; 1996 Dec; 21(12):751-2, 763. PubMed ID: 9812685
[TBL] [Abstract][Full Text] [Related]
28. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of GLUT-4 in right ventricle of rats with monocrotaline-induced pulmonary hypertension.
Broderick TL; King TM
Med Sci Monit; 2008 Dec; 14(12):BR261-4. PubMed ID: 19043358
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms and pathology of monocrotaline pulmonary toxicity.
Wilson DW; Segall HJ; Pan LC; Lamé MW; Estep JE; Morin D
Crit Rev Toxicol; 1992; 22(5-6):307-25. PubMed ID: 1489509
[TBL] [Abstract][Full Text] [Related]
31. Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model.
Zapata-Sudo G; Pontes LB; da Silva JS; Lima LM; Nunes IK; Barreiro EJ; Sudo RT
Eur J Pharmacol; 2012 Sep; 690(1-3):176-82. PubMed ID: 22728079
[TBL] [Abstract][Full Text] [Related]
32. Monocrotaline pyrrole interacts with actin and increases thrombin-mediated permeability in pulmonary artery endothelial cells.
Wilson DW; Lamé MW; Dunston SK; Taylor DW; Segall HJ
Toxicol Appl Pharmacol; 1998 Sep; 152(1):138-44. PubMed ID: 9772209
[TBL] [Abstract][Full Text] [Related]
33. Right ventricle-sparing heart transplantation effective against iatrogenic pulmonary hypertension.
Lovoulos C; Tittle S; Goldstein L; Austin DJ; Singh S; Rocco E; Keane J; Tang P; Kopf GS; Elefteriades JA
J Heart Lung Transplant; 2004 Feb; 23(2):236-41. PubMed ID: 14761772
[TBL] [Abstract][Full Text] [Related]
34. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite.
Roth RA; Reindel JF
Adv Exp Med Biol; 1991; 283():477-87. PubMed ID: 1906225
[TBL] [Abstract][Full Text] [Related]
35. Monocrotaline-induced pulmonary hypertension in Wistar rats.
Rey M; Hess P; Clozel M
Curr Protoc Pharmacol; 2009 Sep; Chapter 5():Unit 5.56. PubMed ID: 22294402
[TBL] [Abstract][Full Text] [Related]
36. Characterization of monocrotaline pyrrole-induced DNA cross-linking in pulmonary artery endothelium.
Wagner JG; Petry TW; Roth RA
Am J Physiol; 1993 May; 264(5 Pt 1):L517-22. PubMed ID: 8498528
[TBL] [Abstract][Full Text] [Related]
37. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
Hilliker KS; Bell TG; Lorimer D; Roth RA
Am J Physiol; 1984 Jun; 246(6 Pt 2):H747-53. PubMed ID: 6742140
[TBL] [Abstract][Full Text] [Related]
38. Endothelial fate mapping in mice with pulmonary hypertension.
Qiao L; Nishimura T; Shi L; Sessions D; Thrasher A; Trudell JR; Berry GJ; Pearl RG; Kao PN
Circulation; 2014 Feb; 129(6):692-703. PubMed ID: 24201301
[TBL] [Abstract][Full Text] [Related]
39. Lack of effect of deferoxamine, dimethyl sulfoxide, and catalase on monocrotaline pyrrole pulmonary injury.
Bruner LH; Johnson K; Carpenter LJ; Roth RA
J Toxicol Environ Health; 1987; 21(1-2):205-17. PubMed ID: 3573071
[TBL] [Abstract][Full Text] [Related]
40. Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Schroll S; Sebah D; Wagner M; Popara V; Pfeifer M; Blumberg F
Respir Physiol Neurobiol; 2013 Mar; 186(1):61-4. PubMed ID: 23246673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
